Last reviewed · How we verify
GcMAF
At a glance
| Generic name | GcMAF |
|---|---|
| Sponsor | S.LAB (SOLOWAYS) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- α-N-acetylgalactosaminidase Levels in Panic Disorder
- Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases (PHASE1, PHASE2)
- Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer (PHASE3)
- Vitamin D in Armenia: Vitamin D Repletion Strategies With Dibase, and Vitamin D and Vitamin D Binding Protein and COVID (NA)
- Evaluation of the Relationship of Vitamin D and Vitamin D Binding Protein with Disease Severity in Pediatric Sars-CoV2
- Isolation of Vitamin D Binding Protein Isoforms From Human Volunteers
- The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases
- Regulatory T Cell With Related Interleukins in Periodontal Disease Progression
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GcMAF CI brief — competitive landscape report
- GcMAF updates RSS · CI watch RSS
- S.LAB (SOLOWAYS) portfolio CI